BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35872471)

  • 1. Prevalence and predictors of neurological manifestations in systemic AL amyloidosis.
    Thimm A; Carpinteiro A; Oubari S; Papathanasiou M; Luedike P; Kessler L; Rischpler C; Blau T; Reinhardt HC; Rassaf T; Schmidt H; Kleinschnitz C; Hagenacker T
    J Neurol Sci; 2022 Sep; 440():120341. PubMed ID: 35872471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromuscular amyloidosis: Unmasking the master of disguise.
    Pinto MV; Dyck PJB; Liewluck T
    Muscle Nerve; 2021 Jul; 64(1):23-36. PubMed ID: 33458861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study.
    Matsuda M; Gono T; Morita H; Katoh N; Kodaira M; Ikeda S
    Eur J Neurol; 2011 Apr; 18(4):604-10. PubMed ID: 20860753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Nervous System Involvement.
    Thaisetthawatkul P; Dyck PJB
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1091-1098. PubMed ID: 33099426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromuscular Complications of Systemic Amyloidosis.
    Namiranian D; Geisler S
    Am J Med; 2022 Apr; 135 Suppl 1():S13-S19. PubMed ID: 35104443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group.
    Mauermann ML; Clarke JO; Litchy WJ; Obici L; Lousada I; Gertz MA;
    Adv Ther; 2023 Nov; 40(11):4695-4710. PubMed ID: 37658177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions.
    Mendelson L; Prokaeva T; Lau KHV; Sanchorawala V; McCausland K; Spencer B; Dasari S; McPhail ED; Kaku MC
    Amyloid; 2023 Dec; 30(4):357-363. PubMed ID: 37140928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
    Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Yong K; Rabin N; Popat R; Kyriakou C; Worthington S; Sharpley F; Smith M; Shah R; Cheesman S; Hawkins PN; Wechalekar AD
    Br J Haematol; 2019 Dec; 187(5):638-641. PubMed ID: 31388995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing neuropathy in multiple myeloma and AL amyloidosis.
    Ballegaard M; Nelson LM; Gimsing P
    J Peripher Nerv Syst; 2021 Mar; 26(1):75-82. PubMed ID: 33368817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathy Associated with Systemic Amyloidosis.
    Kaku M; Berk JL
    Semin Neurol; 2019 Oct; 39(5):578-588. PubMed ID: 31639841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathy, M components, and amyloid.
    Benson MD; Cohen AS; Brandt KD; Cathcart ES
    Lancet; 1975 Jan; 1(7897):10-2. PubMed ID: 46335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral neuropathy as an early marker of AL amyloidosis.
    Duston MA; Skinner M; Anderson J; Cohen AS
    Arch Intern Med; 1989 Feb; 149(2):358-60. PubMed ID: 2537065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin-related (AL) amyloidosis.
    Husby G
    Clin Exp Rheumatol; 1983; 1(4):353-8. PubMed ID: 6442636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
    Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
    Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.
    Caccialanza R; Palladini G; Klersy C; Cereda E; Bonardi C; Cameletti B; Quarleri L; Montagna E; Foli A; Milani P; Lavatelli F; Marena C; Merlini G
    JPEN J Parenter Enteral Nutr; 2014 Sep; 38(7):891-4. PubMed ID: 24072737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release.
    Sperry BW; Reyes BA; Ikram A; Donnelly JP; Phelan D; Jaber WA; Shapiro D; Evans PJ; Maschke S; Kilpatrick SE; Tan CD; Rodriguez ER; Monteiro C; Tang WHW; Kelly JW; Seitz WH; Hanna M
    J Am Coll Cardiol; 2018 Oct; 72(17):2040-2050. PubMed ID: 30336828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of isolated amyloid myopathy.
    Liewluck T; Milone M
    Eur J Neurol; 2017 Dec; 24(12):1437-1445. PubMed ID: 28888072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Amyloid neuropathy].
    Ikegawa S
    Rinsho Shinkeigaku; 1990 Dec; 30(12):1371-3. PubMed ID: 1966018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
    Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
    Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.